I initially rated Aurinia Pharmaceuticals a "Sell" in February 2024, but the stock has since risen over 25%, proving my call incorrect. Lupkynis, Aurinia's sole commercial product, showed ...
Astellas Pharma US, Inc. has issued a recall for one lot of PROGRAF 0.5mg (tacrolimus) and one lot of ASTAGRAF XL 0.5mg (tacrolimus extended-release) capsules. These products are being recalled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback